Rosuvastatin / Ezetimibe — Side Effects

Common Side Effects

Serious / Clinically Important Adverse Effects

1. Musculoskeletal Toxicity (Statin-related)

• Myalgia — muscle pain/weakness without significant CK elevation (most common)
• Myopathy / elevated CK — CK >3–5× baseline; warrants drug cessation
• Rhabdomyolysis — rare but life-threatening; presents with myoglobinuria and acute kidney injury
• Immune-mediated necrotizing myopathy (IMNM) — rare; may progress even after stopping the statin; requires immunosuppression

2. Hepatotoxicity

• Transaminase elevations (ALT/AST >3× ULN) occur in ~1% of patients, dose-dependent
• Severe liver injury is rare but documented
• Baseline LFTs recommended; monitoring if symptomatic
• Contraindicated in active liver disease

3. New-Onset Diabetes Mellitus

• Statins (including rosuvastatin) carry a class-wide modest increase in T2DM risk (~10–12%)
• Risk is higher at higher doses and in patients with pre-diabetes/metabolic syndrome
• Cardiovascular benefit generally outweighs this risk

4. CNS Effects

• Cognitive changes (memory impairment, confusion) — rare, FDA class warning for statins; generally reversible on discontinuation

Ezetimibe-Specific Notes

• Mild hepatic transaminase elevation (additive with statins when combined)
• Pancreatitis (very rare, case reports)
• Hypersensitivity reactions (rash, angioedema — uncommon)

Monitoring Recommendations

Contraindications

• Active liver disease or unexplained persistent transaminase elevations
• Pregnancy and breastfeeding (teratogenic — Category X)
• Concomitant use with certain strong CYP2C9 inhibitors or drugs raising statin levels (dose adjustment required for rosuvastatin with cyclosporine, gemfibrozil)

Clinical note: Rosuvastatin is hydrophilic and has fewer CYP3A4 interactions compared to lipophilic statins (atorvastatin, simvastatin), but it is metabolized via CYP2C9 and transported by OATP1B1/BCRP — interactions with gemfibrozil, atazanavir, lopinavir, and cyclosporine can significantly raise rosuvastatin plasma levels and increase toxicity risk.

Rosuvastatin/Ezetimibe vs. Rosuvastatin Alone

LDL-C Lowering Efficacy

RACING Trial — Head-to-Head Evidence

• Rosuvastatin 20 mg monotherapy
• Rosuvastatin 10 mg + Ezetimibe 10 mg combination

Cardiovascular Outcomes

• LDL-C at 1 year: 53.2 mg/dL (combo) vs. 69.9 mg/dL (statin alone)
• 7-year MACE: 32.7% (combo) vs. 34.7% (statin alone)
• Relative risk reduction: 6.4% (HR 0.936; p = 0.016)
• Absolute risk reduction: 2.0%

Tolerability & Safety Comparison

When to Prefer the Combination

• Patient needs >50% LDL reduction but cannot tolerate high-dose statin
• LDL-C target not met on maximally tolerated statin monotherapy
• High/very high CV risk requiring LDL-C <70 mg/dL (or <55 mg/dL in extreme risk)
• History of SAMS — allows dose reduction while maintaining or improving LDL control
• As a step before escalating to PCSK9 inhibitors (guideline-recommended sequence)

When Rosuvastatin Alone May Suffice

• Mild-to-moderate hyperlipidemia with modest LDL reduction target (~30–45%)
• Patient does not tolerate ezetimibe (rare GI issues)
• Lower CV risk with less stringent LDL targets

Lipid Profile Analysis — 26-Year-Old Athlete

Risk Stratification First

Risk Assessment

1. Lp(a) >90 mg/dL (~225 nmol/L) — Per NLA guidelines (Use of Lp(a) in Clinical Practice, p. 1), ≥125 nmol/L (≈50 mg/dL) is high risk. At >90 mg/dL, this patient is in the very high Lp(a) tier, independently elevating lifetime ASCVD risk 2–4×. Lp(a) is largely genetically fixed and not reduced by statins.
2. APO B 112 mg/dL — APO B reflects atherogenic particle number and is a superior predictor to LDL-C. This value indicates a high burden of atherogenic particles despite a seemingly moderate LDL-C.
3. Low HDL-C (36.7) with low APO A-I (131) — Impaired reverse cholesterol transport.
4. hsCRP 3.4 — Confirms active low-grade inflammation; combined with a lipid disorder, this significantly raises CV risk (JUPITER trial relevance).
5. Elevated TG + VLDL — Suggests residual lipoprotein risk and possible insulin resistance or dietary pattern even in an athlete.
6. Age 26 + weight training 6×/week — Physical activity is protective but does NOT neutralize genetic Lp(a) risk or elevated APO B. Intense resistance training also raises baseline CK, which is important for statin monitoring.

Recommended Regimen

Rosuvastatin/Ezetimibe Dose

Rosuvastatin 10 mg + Ezetimibe 10 mg once daily (fixed combination or co-administration)

• The RACING trial showed Rosuvastatin 10 mg + Ezetimibe 10 mg achieved LDL-C <70 mg/dL in 72–75% of patients vs. only ~58% with Rosuvastatin 20 mg monotherapy — with significantly lower discontinuation (4.8% vs 8.2%).
• In an athlete doing heavy resistance training, starting with a lower statin dose is critical — baseline CK is already elevated from training, making it harder to detect statin-induced myopathy. The combination allows LDL target achievement while minimizing myopathy risk.
• Expected LDL-C reduction: ~55–65% → from 99 mg/dL to approximately 35–45 mg/dL, which is appropriate given the very high Lp(a) burden requiring more aggressive non-Lp(a) lipid lowering to offset overall risk.
• APO B target: <70 mg/dL (high risk) — achievable with this regimen.

Duration

Additional Interventions Beyond Rosuvastatin/Ezetimibe

Summary

Start Rosuvastatin 10 mg / Ezetimibe 10 mg daily, indefinitely. This patient's risk is dominated by a very high genetically-elevated Lp(a) (>90 mg/dL), high APO B, elevated hsCRP, and dyslipidemia — despite appearing "healthy" as a young athlete. The LDL-C of 99 mg/dL underestimates true atherogenic burden. Aggressive long-term lipid lowering targeting APO B <70 mg/dL and LDL <55–70 mg/dL is warranted. A PCSK9 inhibitor should be discussed at 6–12 months if targets are not met or if the Lp(a) concern warrants additional Lp(a) lowering.